First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients


YÜKSEL S., Evrengul H., ÖZÇAKAR Z. B. , Becerir T., Yalcin N., Korkmaz E., ...More

PEDIATRIC DRUGS, vol.18, no.6, pp.413-420, 2016 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 6
  • Publication Date: 2016
  • Doi Number: 10.1007/s40272-016-0194-0
  • Title of Journal : PEDIATRIC DRUGS
  • Page Numbers: pp.413-420

Abstract

Studies relating to first-line, early, and long-term eculizumab treatment and outcomes in children with atypical hemolytic uremic syndrome (aHUS) are scarce and unclear. The aim of this case-series study was to evaluate the outcomes of first-line, early, and long-term eculizumab treatment in our aHUS patients.